Major Depression Clinical Trial
Official title:
Impact of Quetiapine Prolong and Escitalopram on the Hypothalamic-pituitary-adrenocortical (HPA)-Axis Activity in Depressed Patients
In former studies of the investigators research group the investigators could also
demonstrate acute inhibitory effects of the antidepressant mirtazapine on ACTH and cortisol
release in normal controls (Schüle et al. 2002), most likely mediated via antagonism at
central 5-HT2- and H1-receptors. In contrast to mirtazapine, serotonin or norepinephrine
reuptake inhibiting antidepressants acutely stimulate ACTH and cortisol secretion (Schüle
2007). The investigators also performed a study in depressed patients who were treated
either with mirtazapine or with reboxetine using serial dexamethasone/CRH tests (week 0, 1,
and 5) as a parameter for HPA axis activity. Mirtazapine, but not the norepinephrine
reuptake inhibitor reboxetine was able to significantly reduce HPA axis activity already
within one week (Schüle et al. 2006). Mirtazapine is known to have an earlier onset of
antidepressant action than do SSRIs such as sertraline (Behnke et al. 2003) or
antidepressants with dual mechanism of action such as venlafaxine (Benkert et al. 2006),
possibly due to its rapid inhibition of HPA axis activity in unipolar depressed patients.
Since mirtazapine and quetiapine have similar effects on the HPA system in healthy male
volunteers (i.e. inhibition of ACTH and cortisol secretion), a rapid attenuation of HPA axis
activity is also expected during quetiapine XR treatment in depressed patients.
Therefore, in the present study the investigators goal is to investigate whether quetiapine
fumarate XR at a dosage of 300 mg per day has an impact on HPA axis activity in unipolar
depressed patients, as measured by serial dexamethasone/CRH tests (week 0, 1, and 5) and
salivary cortisol profiles and whether putative effects of quetiapine XR on the HPA system
are related to its antidepressant efficacy.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00167310 -
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
|
Phase 2 | |
Completed |
NCT00149110 -
Chronos: the Use of Chronobiological Treatment in Depression
|
N/A |